Lantern Pharma Unveils predictBBB.ai™, a Breakthrough AI Module for Accurately Predicting Blood-Brain Barrier Permeability

Lantern Pharma Inc. (NASDAQ: LTRN), a leader in artificial intelligence-driven oncology drug discovery and development, has announced the public release of predictBBB.ai™, a transformative AI module designed to predict the blood-brain barrier (BBB) permeability of small molecules with unmatched accuracy and scalability. This breakthrough addresses one of the most enduring challenges in pharmaceutical development, where only 2% to 6% of small-molecule drugs successfully cross the BBB to treat central nervous system (CNS) diseases. The BBB acts as a protective shield for the brain, preventing harmful substances from entering. While essential for brain health, this barrier also limits the delivery of potentially life-saving therapeutics for conditions such as brain tumors, Alzheimer’s disease, Parkinson’s disease, and other neurological disorders. Predicting which compounds can effectively penetrate the BBB has long been a bottleneck in drug development, often requiring costly and time-consuming experimental testing. predictBBB.ai™ leverages Lantern Pharma’s proprietary AI platform, which integrates advanced deep learning models with extensive, high-quality chemical and biological datasets. The module enables researchers to rapidly screen thousands of compounds in silico, identifying those with the highest likelihood of BBB penetration early in the discovery pipeline. By reducing reliance on late-stage experimental validation, the tool accelerates drug development timelines and lowers costs. The public release of predictBBB.ai™ marks a significant step in Lantern Pharma’s mission to democratize access to cutting-edge AI tools for drug discovery. The platform is designed to be user-friendly and accessible to researchers across academia, biotech startups, and pharmaceutical companies, regardless of their computational expertise. Lantern Pharma’s CEO, Dr. Michael K. O’Connor, emphasized the strategic importance of the tool: “The blood-brain barrier remains a major obstacle in treating brain diseases. With predictBBB.ai™, we’re giving the scientific community a powerful new weapon to identify promising candidates faster and more efficiently. This is not just an incremental improvement—it’s a paradigm shift in how we approach CNS drug development.” The release comes amid growing demand for AI-powered solutions in oncology and neurology, where the ability to deliver therapeutics to the brain can determine the success of a treatment. Lantern Pharma continues to expand its AI-driven pipeline, with predictBBB.ai™ already being integrated into multiple preclinical programs focused on brain metastases and primary brain tumors. The company plans to further enhance the module with additional predictive capabilities, including metabolic stability and toxicity profiles, in upcoming updates. With predictBBB.ai™ now publicly available, Lantern Pharma is positioning itself at the forefront of the next generation of intelligent drug discovery.